Brammer Bio is a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies. Brammer offers end-to-end CDMO services from Phase I/II in Florida through commercial manufacturing in Massachusetts. Brammer Bio provides clinical and commercial supply of viral vectors for in vivo gene and ex vivo modified-cell based therapies, process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. The Brammer team consists of extraordinary employees focused exclusively on serving the gene therapy needs of clients and their patients.

Contact Brammer Bio
info@brammerbio.com
Visit Website